Cyclosporine impairs the ability of human platelets to mediate vasodilation

Hypertension
H J OskarssonM T Olivari

Abstract

Cyclosporine causes various platelet abnormalities. Whether it affects the ability of platelets to mediate vasodilation is unknown. Platelets were isolated from healthy volunteers and 13 heart transplant patients on cyclosporine. When perfused through preconstricted normal rabbit carotid arteries, activated platelets from transplant patients failed to cause vasorelaxation, whereas normal platelets produced significant vasodilation (-4.0 +/- 1.9% versus 30 +/- 3% [P < .0001] change in vessel diameter, respectively). When normal platelets were exposed to cyclosporine in vitro, they lost their ability to cause vasodilation in a dose- and time-dependent fashion. However, when activated and perfused through quiescent, N omega-nitro-L-arginine-pretreated arteries, platelets from transplant patients and normal platelets caused similar degrees of vasoconstriction. The amount of adenosine triphosphate in the supernatant from activated cyclosporine-exposed and control platelets was similar (1.7 +/- 0.4 versus 1.5 +/- 0.3 mumol/L [P = NS], respectively). However, concomitant perfusion of activated platelets from transplant patients impaired acetylcholine-mediated, endothelium-dependent vasodilation but perfusion of normal platelets did no...Continue Reading

References

Oct 1, 1978·The Journal of Clinical Investigation·R L CzervionkeG L Fry
Jan 1, 1992·Free Radical Research Communications·S KitagawaH Sakurai
Oct 15, 1992·Biochemical and Biophysical Research Communications·Y Nunokawa, S Tanaka
Aug 15, 1991·Archives of Biochemistry and Biophysics·L IulianoF Violi
Jan 1, 1990·International Archives of Allergy and Applied Immunology·B Jahn, G M Hänsch
Jul 1, 1991·The Journal of Clinical Investigation·T E Bunchman, C A Brookshire
Sep 1, 1990·American Journal of Hypertension·D A Laskow, J J Curtis
Sep 13, 1990·The New England Journal of Medicine·U ScherrerR G Victor
Apr 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G Remuzzi, T Bertani
Jun 8, 1989·European Journal of Pharmacology·C BossallerE Fleck
May 1, 1986·The American Journal of Physiology·G M Rubanyi, P M Vanhoutte
Jun 1, 1988·Drug Intelligence & Clinical Pharmacy·P J Weidle, P H Vlasses
Dec 1, 1987·Kidney International·A A GraceP Dandona
Aug 1, 1985·Transplantation·A KawaguchiR R Lower
Mar 1, 1993·Journal of Cardiovascular Pharmacology·W Auch-SchwelkE Fleck
Apr 15, 1994·European Journal of Biochemistry·L IulianoF Violi
Jan 1, 1995·Journal of Cardiovascular Pharmacology·C HaugA Grünert
May 1, 1996·Journal of the American College of Cardiology·H J Oskarsson, T G Hofmeyer

❮ Previous
Next ❯

Citations

Nov 2, 2004·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Marcin TkaczykMichał Nowicki
Mar 22, 2001·Kidney International·M AvernaG Davì
Jan 28, 2004·The Journal of Experimental Medicine·Voahanginirina RandriamboavonjyIngrid Fleming
May 9, 2016·Journal of Veterinary Internal Medicine·J ThomasonA Mackin
May 12, 2018·Journal of Veterinary Internal Medicine·John M ThomasonAndrew J Mackin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.